1. Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?;Gerber;Pharmacoeconomics,2011
2. Pammolli F, Ruggi A, Available at SSRN: http://ssrn.com/abstract-2717501, https://doi.org/10.2139/ssrn.2717501.
3. IMS Institute. Global oncology trend report a review of 2015 and outlook to 2020. June 2016.
4. Elshaug AG, Rosenthal MB, Lavis JN, Brownlee S, Schmidt H, Nagpal S. et al. Levers for addressing medical underuse and overuse: achieving high-value health care. Lancet 2017 July;390 (10090):191-202.
5. AMNOG-Reporting: Auswirkung der frühen Nutzenbewertung auf die Versorgung;IGES,2016